HNF Driving Progress at the 2026 MDA Clinical & Scientific Conference

by | Mar 17, 2026 | 0 comments

HNF Driving Progress at the 2026 MDA Clinical & Scientific Conference

The Hereditary Neuropathy Foundation (HNF) had a strong presence at the 2026 MDA Clinical & Scientific Conference in Orlando last week, where more than 1,900 leaders across science, medicine, industry, and patient advocacy gathered to advance neuromuscular research. Throughout the conference, HNF Founder and CEO Allison Moore helped lead conversations shaping the future of Charcot-Marie-Tooth disease (CMT) research and therapy development.

Honored with the Donavon Decker Legacy Award

A highlight of the conference was Moore receiving the MDA Donavon Decker Legacy Award for Community Impact in Research, recognizing her decades of leadership in advancing research and amplifying the patient voice.

In her acceptance remarks, Moore reminded the audience of the human impact behind scientific progress:

“Behind every data point is a human being brave enough to say yes to hope — not just for themselves, but for everyone who follows.”

Moore founded HNF in 2001 after her own diagnosis with CMT. Since then, the organization has helped build critical research infrastructure for CMT and related inherited neuropathies, including the Global Registry for Inherited Neuropathies (GRIN), the CMT Biobank, and the TRIAD Research Accelerator.

Advancing Research and Trial Readiness

HNF-supported research was also featured during the poster sessions. Dr. Kayla Cornett of the University of Sydney presented findings from HNF’s digital wearable study, which uses remote monitoring technology to measure daily activity and mobility in people with CMT, helping researchers capture real-world functional outcomes for clinical trials.

Dr. Cornett also presented the CMT-CERTIFY training program, a collaborative initiative designed to ensure clinical trial sites are fully prepared to evaluate CMT patients and collect reliable outcome measures across global research centers. HNF provided the infrastructure and patients at the CMT Clinical Trial Readiness Summit 2025, where over 30 clinicians were certified in the CMT Outcome instruments (CMT-FOM & CMTPedS), an essential component of clinical trial readiness.

Accelerating Partnerships and Industry Engagement

Moore also served as a panel speaker on “AI and the Future of Clinical Trial Design and Execution,” bringing the patient advocacy perspective to discussions on how technology can improve trial design and patient participation.

Throughout the conference, HNF met with academic researchers, clinicians, biotechnology companies, and pharmaceutical partners to strengthen collaborations aimed at moving CMT therapies more rapidly through the development pipeline. Engagements with companies such as TRIAD partner, NMD Pharma reflect HNF’s role in ensuring the patient voice is integrated into clinical trial design, outcome measures, and recruitment strategies.

Connecting the Global CMT Community

HNF also met with neuromuscular clinicians from clinics around the world, sharing HNF’s patient resources and opportunities for collaboration.

Moore emphasized the importance of aligning clinical care and patient experience:

“Clinicians see the medical journey of CMT, but patients live the daily reality of it. When we bring those perspectives together — and connect them to research — we create the foundation for better trials, better care, and ultimately better outcomes.”

Throughout the conference, the HNF Patient Advocacy Table served as a hub for connecting with neuromuscular disease advocates, patients, families, researchers, and industry leaders.

As Moore shared in her speech:

“Together we have moved research forward — step by step, discovery by discovery, patient by patient.”

HNF remains committed to ensuring the voice of the CMT community continues to drive innovation, partnerships, and progress toward therapies and ultimately cures.

Make a CMT Difference!

Turn CMT Symptoms into Science by joining HNF’s Global Patient Registry.

Connect with CMT families, researchers, and changemakers at the CMT Summit + Retreat on April 16-18, in Ellicott City, MD!

Learn more on this topic

Related Blog Posts

Q & A with Andy Heck

Q & A with Andy Heck

Our Q&A for the Winter CMT Update is Andy Heck. Andy has been diagnosed with Charcot-Marie-Tooth since four and doesn’t let CMT stop him for living his life to the fullest!

Scientific Advisory Board Meeting

Scientific Advisory Board Meeting

On the 7th of November we convened our scientific advisory board meeting at the HNF offices in NY. We have written a detailed review that has been published and captures all of the discussion and make this freely available to the scientific community.

Breaking News: First Therapeutic Gene Therapy to Treat an Inherited Neuropathy is Approved for Clinical Trial!

The first disease community to receive a therapeutic gene to the spinal cord for an ultra rare inherited neuropathy is Giant Axonal Neuropathy (GAN). Congratulations to Hannah’s Hope Fund (HHF), a 501(c)3 public charity, which has driven this collaborative research in less than six years. Six million dollars has been raised to date to fund pre-clinical and clinical research on this rare disease.

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

PARIS, December 18th, 2014 – Pharnext SAS today announced the proof of concept of its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases. Indeed, Pharnext’s lead pleodrug, PXT-3003, has shown positive results both in preclinical and Phase 2 clinical studies published today in the Orphanet Journal of Rare Diseases.

Living with CMT: Key Topics

There are a number of adaptive aids that can help make everyday tasks easier. This section lists just a few of them. Some of these items can be adapted from materials at home, others must be purchased.

From the words of a CMT Hero

From the words of a CMT Hero

“FAITH, LOVE AND HOPE KEEPS TIMMY DIXON GOING!”

I often wonder what it’s like to be like everyone else out there. How great it would be to do things most consider easily accessible and within reach. I believe in myself; it’s not really about that. Sometimes I just feel alone, cold, and bitter after considering life in general. Then I ponder a thought: there are too many hurdles I’ve already jumped over

Allison Moore is going to be published!

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news